Page 4 - Phasei Ii News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Phasei ii. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Phasei Ii Today - Breaking & Trending Today

Gilead, Merck to team up on potential HIV combo treatment

Gilead, Merck to team up on potential HIV combo treatment
The two major pharmaceutical firms have agreed to jointly develop and commercialize treatment combinations of lenacapavir and islatravir in HIV patients.
Gilead Sciences and Merck have entered into an agreement to co-develop and co-commercialize long-acting treatments in HIV. The intended solutions will combine Gilead’s investigational capsid inhibitor, lenacapavir, and Merck’s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir, into a two-drug regimen with the potential to provide new, meaningful treatment options for people with HIV.
Islatravir and lenacapavir are potentially first-in-class medicines in late-stage clinical trials, with significant clinical data generated for both to date. Each of the medicines reportedly has a long half-life and has demonstrated activity at low dosages in clinical studies, which support development as an investi ....

Kenneth Frazier , Gilead Sciences , Danielo Day , Clinical Development , Preclinical Research , Mergers And Acquisitions , Clinical Evolution , Phasei Ii , Phase Iii Iv , கெநெத் ப்ராஜிேர் , கிலியட் அறிவியல் , மருத்துவ வளர்ச்சி , இணைப்புகள் மற்றும் கையகப்படுத்துதல் , மருத்துவ பரிணாமம் , கட்டம் ஈயீ இவ் ,

IQVIA announces growth in customer engagement solution

The Orchestrated Customer Engagement Technology reportedly has been adopted by 140 life sciences companies (including top-10 pharma firms) in nearly 90.
IQVIA has announced its Orchestrated Customer Engagement (OCE) solution is now in use by 140 life-sciences companies located in 90 countries. The most recent to sign on, Laboratoires Thea, is an independent eye-care group in Europe.
The company reports its clients are leveraging OCE to accelerate their global digital transformation, in order to lead to more impactful interactions with customers. Customers now include AstraZeneca, Novo Nordisk, Roche, Adhera Therapeutics, Napo Pharmaceuticals, Pierre Fabre Pharmaceuticals, PruGen Pharmaceuticals, Recordati, Theramex and Zentiva.
Susan Hill, vice president and general manager of customer engagement with IQVIA, told Outsourcing-Pharma that the COVID-19 pandemic has created a need for accelerated digital adoption in pharma development firms. ....

Susan Hill , Laboratoires Thea , Napo Pharmaceuticals , Prugen Pharmaceuticals , Pierre Fabre Pharmaceuticals , Novo Nordisk , Orchestrated Customer Engagement , Adhera Therapeutics , Clinical Development , Covid 19 , Clinical Evolution , Contract Manufacturing , Phasei Ii , Phase Iii Iv , Data Management , சூசன் மலை , நாபொ மருந்துகள் , பியர் ஃபேப்ரே மருந்துகள் , மருத்துவ வளர்ச்சி , மருத்துவ பரிணாமம் , ஒப்பந்த உற்பத்தி , கட்டம் ஈயீ இவ் , தகவல்கள் மேலாண்மை ,

Home health monitoring provides valuable patient insights

(ake1150sb/iStock via Getty Images Plus)
A leader from the trial solutions provider discusses how the COVID-19 pandemic has accelerated the already growing interest in remote patient monitoring.
Outsourcing-Pharma recently spoke with Stewart Whiting, chief technical officer of Current Health, about how the use of home health monitoring has evolved in the month leading up to the pandemic, its new Community by Current Health offering, and what the landscape might look like in the years ahead.
OSP: Could you please share Current Health’s perspective on the industry’s evolving acceptance and use of at-home health monitoring?
SW: At-home monitoring has been around for over a decade, but only recently have we begun to see care delivery models fundamentally shift as a result of this technology. Largely, this is because new monitoring solutions can provide far more sophisticated visibility into patient health. Paired with advances in data ....

Stewart Whiting , Centers For Medicare , Human Services , Us Department Of Health , Medicaid Service , Current Health , Biomedical Advanced Research Development Association , Mount Sinai , With Current Health , Patient Centricity , Clinical Development , Covid 19 , Clinical Evolution , Data Management , Phasei Ii , Phase Iii Iv , Remote Patient Monitoring , Clinical Trials , Decentralized Trials , Virtual Clinical Trials , ஸ்டீவர்ட் வெள்ளை , மையங்கள் க்கு மருத்துவ , மனிதன் சேவைகள் , எங்களுக்கு துறை ஆஃப் ஆரோக்கியம் , மருத்துவ உதவி சேவை , தற்போதைய ஆரோக்கியம் ,

Thermo Fisher Scientific expands DTP trial service offerings

Thermo Fisher Scientific expands DTP trial service offerings
(ADragan/iStock via Getty Images Plus)
The direct-to-patient service is designed to support trials and help to minimize trial length and costs, while boosting enrollment and participation rates.
Thermo Fisher Scientific has expanded its direct-to-patient (DTP) service offerings. The range now includes clinical site-to-patient, pharmacy-to-patient, and depot-to-patient services, so that patients can receive medication and supplies directly to their homes.
The DTP service builds on Thermo Fisher Scientific’s clinical site-to-patient offering that launched earlier in 2020, designed to make sure trial participants have access to life-saving investigational drug shipments with no need to travel to a clinic. The services are available in 47 different countries. ....

Thermo Fisher , Thermo Fisher Scientific , Investigational Medicinal Products , Does Thermo Fisher Scientific , Clinical Development , Contract Manufacturing Amp Logistics , Patient Centricity , Clinical Evolution , Phasei Ii , Phase Iii Iv , Supply Chain , Decentralized Trials , Patient Engagement , Trial Supply Management , தெர்மோ மீனவர் , தெர்மோ மீனவர் அறிவியல் , செய்யும் தெர்மோ மீனவர் அறிவியல் , மருத்துவ வளர்ச்சி , ஒப்பந்த உற்பத்தி ஆம்ப் தளவாடங்கள் , மருத்துவ பரிணாமம் , கட்டம் ஈயீ இவ் , விநியோகி சங்கிலி , நோயாளி நிச்சயதார்த்தம் , சோதனை விநியோகி மேலாண்மை ,

ObvioHealth announces upgraded decentralized trial platform

ObvioHealth announces upgraded decentralized trial platform
The company’s technology facilitates remote patient monitoring and integrates with a wide range of wearable sensors for checking patient vital signs.
ObvioHealth has introduced a new platform that enables advanced remote-patient monitoring capabilities for decentralized trial solutions. The company’s decentralized platform and patient-centric smartphone app are designed to help create an ‘ecosystem’ of technology and devices approved by the US Food and Drug Administration (FDA) to support remote monitoring and patient connections with the help of the app.
Through partnerships with other companies like BioIntelliSense, AliveCor and iHealth, trial teams can remotely monitor up to 20 different vital signs, such as heart rate, respiratory rate, temperature, blood pressure, oxygen saturation, ECG, coughing episodes, sweat, sleep, activity levels and body positioning. Data from th ....

New York , United States , Ij Ivan Jarry , Ivan Jarry , Drug Administration , Clinical Development , Covid 19 , Patient Centricity , Clinical Evolution , Data Management , Medical Devices , Phasei Ii , Phase Iii Iv , Decentralized Trials , Remote Patient Monitoring , Application Software , Virtual Clinical Trials , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , ஜ் இவன் ஜார்ரி , இவன் ஜார்ரி , மருத்துவ வளர்ச்சி , மருத்துவ பரிணாமம் , தகவல்கள் மேலாண்மை , மருத்துவ சாதனங்கள் , கட்டம் ஈயீ இவ் ,